cpcuniverse (@cpcuniverse) 's Twitter Profile
cpcuniverse

@cpcuniverse

A tool for Concept-Centered Case-based Learning
Explore the last 50+ years of one of the oldest case series from the NEJM

ID: 1303754852632113153

linkhttp://universeofcpc.com calendar_today09-09-2020 17:59:22

138 Tweet

289 Takipçi

20 Takip Edilen

cpcuniverse (@cpcuniverse) 's Twitter Profile Photo

So excited our work is in this fantastic journal for medicine and medicine education. Looking forward to seeing everyone and demonstrating on VMR with The Clinical Problem Solvers

cpcuniverse (@cpcuniverse) 's Twitter Profile Photo

Thank you so much The Clinical Problem Solvers for having me on VMR! Here are the two cases we discussed: tinyurl.com/4rhfbmaf tinyurl.com/bd6t4tt2 One more of the 5 cases with Case 1 Dx in NEJM: tinyurl.com/yc25dj32 And thanks to NEJM CPC for creating such an amazing education resource

Madellena (Maddy) Conte (@madellenac) 's Twitter Profile Photo

This approach was inspired by the NEJM case Travis Zack presented on Friday's VMR (9/23) to showcase the cpcuniverse — a phenomenal tool to filter NEJM CPC cases by symptom, final diagnosis, etc. so that you can find cases relevant to your learning universeofcpc.com

UC Joint Computational Precision Health Program (@ucjointcph) 's Twitter Profile Photo

Admission period is open! Applying to grad school? The UC Joint Computational Precision Health Program program admission application can be found below: #gradschool #AcademicChatter #STEM #deib #MachineLearning #health #Statistics #biostats grad.berkeley.edu/program/comput…

cpcuniverse (@cpcuniverse) 's Twitter Profile Photo

The two most two important parts of research are asking the right question and having the tools to answer it! This PhD program is designed to give students the background required to do that for CS applications in Health and Medicine. Consider Applying!

Reza (@dxrxedu) 's Twitter Profile Photo

Rabih and I started our journey together. He is my best friend and my younger brother. rlrcpsolvers.com is our dream project. Come learn with us. Our goal is to make medicine fun, easy, and applicable to your patients. Also thrilled Aaron Berkowitz joined the project.

Rabih Geha (@rabihmgeha) 's Twitter Profile Photo

A dream come true to have the space to fully express our passion for clinical reasoning & teaching. On a personal note, it's the deepest expression of the depth of our relationship, and how eager we are to spread love and joy within medicine Join us - RLRcpsolvers.com

Andrew Olson, MD (@andrewolsonmd) 's Twitter Profile Photo

I always feel like I’m an intern back UCSF IM Chiefs at the VA San Francisco on rounds presenting to this amazing and kind attending. Many years later, still learning and full of gratitude for a field I love full of the best people. #SIDM2022

Atul Butte (@atulbutte) 's Twitter Profile Photo

Great example from Madhumita Sushil… #ChatGPT off-the-shelf looking at cancer progress note (deidentified) can yield the biomarkers buried in that note! Of course this still needs supervision. #acentrus23

Great example from <a href="/madhumitasushil/">Madhumita Sushil</a>… #ChatGPT off-the-shelf looking at cancer progress note (deidentified) can yield the biomarkers buried in that note! Of course this still needs supervision. #acentrus23
Pranav Rajpurkar (@pranavrajpurkar) 's Twitter Profile Photo

1/ 📢 New paper alert! Pancreatic cancer lacks actionable biomarkers for precision therapy. We developed an AI-derived histologic signature that can predict treatment outcomes for a specific chemotherapy from pancreatic tumor resections. cell.com/cell-reports-m… Key points ⬇️

Pranav Rajpurkar (@pranavrajpurkar) 's Twitter Profile Photo

2/ We report an AI approach to histologic feature examination that extracts a signature predictive of disease-specific survival in patients with pancreatic ductal adenocarcinoma (PDAC) receiving adjuvant gemcitabine.

2/ We report an AI approach to histologic feature examination that extracts a signature predictive of disease-specific survival in patients with pancreatic ductal adenocarcinoma (PDAC) receiving adjuvant gemcitabine.
Pranav Rajpurkar (@pranavrajpurkar) 's Twitter Profile Photo

3/ 🧬Existing transcriptomic subtypes failed to stratify disease-related outcomes in this cohort, highlighting the need for novel predictive biomarkers.

3/ 🧬Existing transcriptomic subtypes failed to stratify disease-related outcomes in this cohort, highlighting the need for novel predictive biomarkers.
Pranav Rajpurkar (@pranavrajpurkar) 's Twitter Profile Photo

4/ 💻The AI-generated histologic signature is derived from H&E slides and does not require complex molecular testing, making it a cost-effective and efficient tool.

4/ 💻The AI-generated histologic signature is derived from H&amp;E slides and does not require complex molecular testing, making it a cost-effective and efficient tool.
Pranav Rajpurkar (@pranavrajpurkar) 's Twitter Profile Photo

5/ 👥Our visual pancreatic gemcitabine (VPG) signature has potential clinical implications in identifying which patients will benefit from gemcitabine-based therapy after resection and could improve the process of designing clinical trials for PDAC.

5/ 👥Our visual pancreatic gemcitabine (VPG) signature has potential clinical implications in identifying which patients will benefit from gemcitabine-based therapy after resection and could improve the process of designing clinical trials for PDAC.
Pranav Rajpurkar (@pranavrajpurkar) 's Twitter Profile Photo

6/ 🌟We find that VPG signature is predictive of treatment-related outcomes rather than a prognostic marker. Distinction is critical in the development of personalized medicine approaches that aim to identify patients most likely to benefit from a specific treatment.

6/ 🌟We find that VPG signature is predictive of treatment-related outcomes rather than a prognostic marker.
  
Distinction is critical in the development of personalized medicine approaches that aim to identify patients most likely to benefit from a specific treatment.
Aaron Logan, MD, PhD, MPhil (@hemedoc) 's Twitter Profile Photo

#ASCO23 #mdssm Zeidan: transfusion independence at 8 wks 40% w Imetelstat vs 15% placebo. 13.6% vs 1.7% at one year.median DOR 52 vs 13 weeks. Median 3.6g/dL rise in Imetelstat arm vs 0.8 w placebo (wow!).

#ASCO23 #mdssm Zeidan: transfusion independence at 8 wks 40% w Imetelstat vs 15% placebo. 13.6% vs 1.7% at one year.median DOR 52 vs 13 weeks. Median 3.6g/dL rise in Imetelstat arm vs 0.8 w placebo (wow!).